Dexcom (DXCM) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Past insider buys here: 1 of 1 beat the S&P 500 over the next 90 days (small sample). See each one ↓
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 28, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Michael Jon Brown, General Counsel sold 1,700 shares at $83.46 ($142K).
- Trade date
- Nov 16, 2026
- Disclosed to the SEC
- Nov 18, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All DXCM insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
DXCM insider transactions (Form 4)
Open-market purchases and sales. 57 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 18SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,70095,034 held (−2%) | $83.46 | $142K | -4.9% | — |
| Oct 28SEC | Sadie SternEvp Chief People & Culture Off | Sell Plan | 2,565120,913 held (−2%) | $78.62 | $202K | +0.9% | — |
| Oct 19SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,70098,185 held (−2%) | $85.48 | $145K | -7.2% | — |
| Sep 30SEC | Sadie SternEvp Chief People & Culture Off | Sell Plan | 2,565123,478 held (−2%) | $86.15 | $221K | -7.9% | — |
| Sep 16SEC | Nicholas AugustinosDirector | Sell Plan | 6,53929,293 held (−18%) | $84.04 | $550K | -5.6% | — |
| Sep 16SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,70099,885 held (−2%) | $84.04 | $143K | -5.6% | — |
| Sep 16SEC | Nicholas AugustinosDirector | Sell Plan | 1,55035,832 held (−4%) | $84.02 | $130K | -5.5% | — |
| Sep 14SEC | Jereme M. SylvainEvp, Chief Financal Officer | Sell Plan | 3,638146,828 held (−2%) | $83.27 | $303K | -4.7% | — |
| Aug 28SEC | Sadie SternEvp Chief People & Culture Off | Sell Plan | 2,565126,043 held (−2%) | $88.37 | $227K | -10.2% | — |
| Aug 24SEC | Kevin R. SayerChair | Sell Plan | 19,308309,662 held (−6%) | $89.71 | $1.7M | -11.5% | — |
| Aug 24SEC | Kevin R. SayerChair | Sell Plan | 7,351302,311 held (−2%) | $90.78 | $667K | -12.6% | — |
| Aug 24SEC | Kevin R. SayerChair | Sell Plan | 97302,214 held (−0%) | $91.41 | $9K | -13.2% | — |
| Aug 17SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700102,953 held (−2%) | $91.93 | $156K | -13.7% | — |
| Aug 13SEC | Bridgette P. HellerDirector | Sell Plan | 1,01229,570 held (−3%) | $88.29 | $89K | -10.1% | — |
| Aug 4SEC | Mark G. FolettaDirector | Sell Plan | 2,00048,852 held (−4%) | $85.32 | $171K | -7.0% | — |
| Aug 4SEC | Mark G. FolettaDirector | Sell Plan | 2,00050,852 held (−4%) | $80.00 | $160K | -0.8% | — |
| Jul 21SEC | Kevin R. SayerChair | Sell Plan | 26,756328,970 held (−8%) | $76.32 | $2.0M | +4.0% | — |
| Jul 16SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700104,653 held (−2%) | $74.42 | $127K | +6.6% | — |
| Jul 7SEC | Kevin R. SayerChair | Sell Plan | 26,756355,726 held (−7%) | $72.00 | $1.9M | +10.2% | — |
| Jun 17SEC | Mark G. FolettaDirector | Sell Plan | 3,80153,051 held (−7%) | $74.10 | $282K | +7.1% | — |
| Jun 17SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700106,353 held (−2%) | $75.55 | $128K | +5.0% | — |
| Jun 17SEC | Mark G. FolettaDirector | Sell Plan | 19952,852 held (−0%) | $74.82 | $15K | +6.1% | — |
| Jun 5SEC | Jon ColemanEvp, Chief Commercial Officer | Sell Plan | 4,91195,450 held (−5%) | $74.13 | $364K | +7.1% | — |
| Jun 5SEC | Jon ColemanEvp, Chief Commercial Officer | Sell Plan | 4,912100,361 held (−5%) | $73.00 | $359K | +8.7% | — |
| May 26SEC | Kevin R. SayerChair | Sell Plan | 26,759382,482 held (−7%) | $72.00 | $1.9M | +10.2% | — |
| May 19SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700109,504 held (−2%) | $59.91 | $102K | +32.5% | — |
| May 14SEC | Bridgette P. HellerDirector | Sell Plan | 1,01225,007 held (−4%) | $60.01 | $61K | +32.2% | — |
| Apr 16SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700111,204 held (−2%) | $63.04 | $107K | +25.9% | — |
| Mar 18SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700112,904 held (−1%) | $64.85 | $110K | +22.4% | — |
| Feb 17SEC | Bridgette P. HellerDirector | Sell Plan | 1,01226,019 held (−4%) | $68.01 | $69K | +16.7% | — |
| Nov 17SEC | Richard Alexander CollinsDirector | Sell Plan | 2,90635,088 held (−8%) | $59.05 | $172K | +34.4% | — |
| Nov 12SEC | Bridgette P. HellerDirector | Sell Plan | 1,01227,031 held (−4%) | $58.07 | $59K | +36.7% | — |
| Nov 10SEC | Jacob Steven LeachCOO, PresidentFirst buy | Buy | 15,700329,197 held (+5%) | $54.98 | $863K | +44.4% | — |
| Nov 10SEC | Richard Alexander CollinsDirector | Sell Plan | 3,94837,994 held (−9%) | $55.17 | $218K | +43.8% | — |
| Nov 10SEC | Jacob Steven LeachCOO, PresidentFirst buy | Buy | 2,500331,697 held (+1%) | $55.43 | $139K | +43.2% | — |
Similar past setups: not applicable. DXCM has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with DXCM in the Research Lab
Pre-set to DXCM's latest insider buy of $10K or more (Nov 10, 2025: Jacob Steven Leach, $1.0M). Tap to change anything.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
- After DXCM's buys7, 30 and 90 days later, losses included
- Find buys like this"insiders bought over $1M after a 20% drop in the last 12 months"
- Compare DXCM vs KODInsider buying and selling side by side
- DXCM's board links6 companies share insiders with DXCM
- Play Insider Call5 real buys a day: guess which beat the market
Share price and insider trades
Dexcom insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $12.7M of DXCM stock on the open market; P/E 37.6 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
DXCM insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $489K | 3 |
| Q3 2026 | — | 0 | $8.7M | 16 |
| Q2 2026 | — | 0 | $3.3M | 9 |
| Q1 2026 | — | 0 | $179K | 2 |
| Q4 2025 | $1.0M | 2 | $448K | 3 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Dexcom insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $12.7M. 33 of 33 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
DXCM earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 29, 2026 | -7.6% | Sold $347K | +4.7%S&P -2.1% | pending |
| Jul 30, 2026 | +1.4% | Sold $4.1M | +11.1%S&P +2.4% | +8.8% |
| Apr 30, 2026 | -8.6% | Sold $107K | +6.6%S&P +1.3% | +20.2% |
| Feb 12, 2026 | -7.5% | None | +2.7%S&P -1.5% | -8.3% |
| Jan 12, 2026 | -0.0% | None | +4.2%S&P -0.0% | -7.4% |
| Oct 30, 2025 | +3.0% | None | -14.6%S&P -0.8% | +9.0% |
| Jul 30, 2025 | +4.7% | None | -9.6%S&P -0.5% | -6.7% |
| May 1, 2025 | +3.1% | None | +14.3%S&P +2.2% | +5.1% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
DXCM short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded DXCM
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Tina SmithSenate | Sold $100,001 - $250,000 | May 7, 2026 | May 10, 2026 | +30.3% |
| Tina SmithSenate | Sold $100,001 - $250,000 | Apr 29, 2026 | May 10, 2026 | +37.9% |
| John BoozmanSenate | Bought $1,001 - $15,000 | Jan 26, 2026 | Feb 15, 2026 | +8.2% |
What happened after DXCM insiders bought
Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.
| Filed | Insider | Bought | 7 days | 30 days | 90 days |
|---|---|---|---|---|---|
| Nov 10, 2025 | Jacob Steven LeachCOO, President | $1.0M | +6.7%+9.0% vs S&P | +23.2%+22.3% vs S&P | +27.9%+25.8% vs S&P |
Insiders at Dexcom
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Kevin R. SayerChair | — | $8.3M | Aug 24, 2026 | — | — |
| Jacob Steven LeachCEO, President | $1.0M | — | Nov 10, 2026 | — | — |
| Michael Jon BrownGeneral Counsel | — | $1.2M | Nov 18, 2026 | — | — |
| Jon ColemanEvp, Chief Commercial Officer | — | $723K | Jun 5, 2026 | — | — |
| Nicholas AugustinosDirector | — | $680K | Sep 16, 2026 | — | — |
| Sadie SternEvp Chief People & Culture Off | — | $649K | Nov 10, 2026 | — | — |
| Mark G. FolettaDirector | — | $627K | Aug 4, 2026 | 0 of 1 | — |
| Richard Alexander CollinsDirector | — | $389K | Jun 1, 2026 | — | — |
| Jereme M. SylvainCFO, COO | — | $303K | Nov 10, 2026 | — | — |
| Bridgette P. HellerDirector | — | $278K | Aug 13, 2026 | — | — |
| Euan A. AshleyDirector | — | — | Nov 3, 2026 | — | — |
| Glenn S. BoehnleinDirector | — | — | Sep 10, 2026 | — | — |
| Renee D. GalaDirector | — | — | Jun 1, 2026 | — | — |
| Rimma DriscollDirector | — | — | Jun 1, 2026 | — | — |
| Albert Frederick Osterloh IVDirector | — | — | Jun 1, 2026 | — | — |
| Kyle MaladyDirector | — | — | Jun 1, 2026 | — | — |
| Steven R. AltmanDirector | — | — | Jun 1, 2026 | — | — |
Board links: companies that share insiders with DXCM
Directors and executives who filed Form 4s for DXCM and another company in the last 12 months.
- AAgilent Technologies Glenn S. Boehnlein Director here · Director at A · latest filing Sep 10, 2026
- AMNAmn Healthcare Services Mark G. Foletta Director here · Director at AMN · latest filing Aug 4, 2026
- JAZZJazz Pharmaceuticals Renee D. Gala Director here · CEO, President at JAZZ · latest filing Nov 5, 2026
- SNESSenesTech Jacob Steven Leach CEO, President here · Director at SNES · latest filing Nov 10, 2026
- VZVerizon Kyle Malady Director here · CEO at VZ · latest filing Nov 18, 2026
- ZTSZoetis Rimma Driscoll Director here · President at ZTS · latest filing Jun 1, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
DXCM stock: common questions
Are Dexcom insiders buying DXCM stock?
No. No Dexcom insider reported an open-market purchase of DXCM in the past 12 months. The latest was COO, President Jacob Steven Leach bought $863K of DXCM at $54.98 — first open-market purchase in our records.
Are Dexcom insiders selling DXCM stock?
8 insiders reported sales worth $12.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is DXCM's P/E ratio?
DXCM trades at about 37.6 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is DXCM's 52-week range?
Over the past year DXCM has traded between $57.56 and $92.34. It last closed at $79.36 on Nov 19, 2026.